Dr. Gullapalli is responsible for providing strategic scientific and technical leadership in areas of softgel, liquid-filled hard capsules, and novel drug delivery technologies for Pii's contract development and manufacturing business.
"Prasad's extensive background in oral dosage form development adds to Pii's leadership position as a foremost provider of oral dosage form development and GMP manufacturing services to the pharmaceutical industry" said Steve King, senior vice president of Pii. "We look forward to him helping us continually grow our oral formulation development capabilities."
Prior to joining Pii, Dr. Gullapalli served as an associate director of Elan Pharmaceuticals, where he was responsible for preformulation and oral dosage form development. He also served in various scientific positions with increasing responsibilities at Chiron Corporation, Purdue Pharma, Banner Pharmacaps and R.P. Scherer (now Catalent). During his career, Dr. Gullapalli has had extensive experience in the development and manufacturing of a broad range of dosage forms including softgels, liquid-filled hard capsules, nanosuspensions, suspensions, solutions, and controlled release tablets and capsules for highly insoluble and soluble compounds.
Dr. Gullapalli holds a Ph.D. in Pharmaceutics form the University of Tennessee, Memphis and a Masters in Pharmacy in Phamracology from Andhra University (India). He holds Regulatory Affairs Certification (RAC-US) and is experienced in the FDA and EMA CMC regulatory submissions. Dr. Gullapalli is an invited guest lecturer at the University of California at Davis and authored/co-authored several publications in professional journals and presentations at national conferences. He is also an inventor/co-inventor of several patents and patent applications.
"Prasad's extensive background in oral dosage form development adds to Pii's leadership position as a foremost provider of oral dosage form development and GMP manufacturing services to the pharmaceutical industry" said Steve King, senior vice president of Pii. "We look forward to him helping us continually grow our oral formulation development capabilities."
Prior to joining Pii, Dr. Gullapalli served as an associate director of Elan Pharmaceuticals, where he was responsible for preformulation and oral dosage form development. He also served in various scientific positions with increasing responsibilities at Chiron Corporation, Purdue Pharma, Banner Pharmacaps and R.P. Scherer (now Catalent). During his career, Dr. Gullapalli has had extensive experience in the development and manufacturing of a broad range of dosage forms including softgels, liquid-filled hard capsules, nanosuspensions, suspensions, solutions, and controlled release tablets and capsules for highly insoluble and soluble compounds.
Dr. Gullapalli holds a Ph.D. in Pharmaceutics form the University of Tennessee, Memphis and a Masters in Pharmacy in Phamracology from Andhra University (India). He holds Regulatory Affairs Certification (RAC-US) and is experienced in the FDA and EMA CMC regulatory submissions. Dr. Gullapalli is an invited guest lecturer at the University of California at Davis and authored/co-authored several publications in professional journals and presentations at national conferences. He is also an inventor/co-inventor of several patents and patent applications.
Companies in this article
